Research and projectsList of all projects

List of all projects Corect

Duration Duration: 2011–2018

Contracting authority Contracting authority: Czech Society for Oncology

Terminated clinical registry of colorectal cancer (CRC) patients who were treated with cetuximab (Erbitux®), bevacizumab (Avastin®) and/or panitumumab (Vectibix®).

The Corect registry focused on the collection of epidemiological and clinical data on mCRC patients treated with targeted therapies in the Czech Republic.

Over several years, the number of targeted therapies for colorectal cancer gradually rose, and so did the number of Czech drug registries which were launched to monitor treatment of mCRC with individual targeted drugs; namely Erbitux and Avastin (part of the registry dealing with mCRC), which monitored treatment with cetuximab (Erbitux®) and bevacizumab (Avastin®), respectively. The Board of the Czech Society for Oncology therefore agreed to solve this complicated situation by creating a new unified registry which would integrate all data collected so far within original registries. Apart from drugs which were previously monitored in the above-mentioned registries, the Corect registry also monitored treatment with panitumumab (Vectibix®) – a new targeted therapy which has become available only recently. If a new drug was approved by health care payers for targeted mCRC treatment, it could be easily integrated into the Corect registry.

Data collected previously in the above-mentioned registries were transferred into the Corect registry. This procedure has eliminated the necessity of entering data on treatment of any given mCRC patient into several different registries; moreover, coherent and well-arranged information was obtained on the overall treatment of that patient, the potential sequence of targeted therapies, and the patient’s response to treatment. The new project therefore not only improved the quality of collected data, but also simplified the work for registry users. Apart from providing epidemiological characteristics of mCRC patients, the registry also enabled researchers to assess risk factors on patients’ survival and to analyse adverse effects. The registry was also used to make pharmacoeconomic assessments such as planning costs for cancer therapy. The project had been initiated in April 2011 at the Institute of Biostatistics and Analyses of the Masaryk University (IBA MU) and continued at the Institute of Biostatistics and Analyses Ltd (IBA Ltd), a university company.

Primary objective of the project:

  • monitoring the overall number of mCRC patients in the Czech Republic treated with cetuximab, bevacizumab and panitumumab.

Secondary objectives of the project:

  • assessment of effectiveness of targeted therapies in routine clinical practice (separately for each line of treatment):
    • overall survival, defined as the period from the start of treatment by a given drug to a patient’s death (surviving patients were censored with respect to the date of last treatment assessment, loss to follow-up, or end of study),
    • progression-free survival, defined as the period from the start of treatment by a given drug to disease progression or death,
    • patients’ response to treatment (complete response, partial response, disease stabilisation, disease progression according to RECIST - Response Evaluation Criteria In Solid Tumors)
  • assessment of profile of targeted therapies in everyday clinical practice,
  • epidemiological analysis of records on mCRC patients.

Other important information:

  • Expert guarantor: Katarína Petráková, MD, PhD (Czech Society for Oncology)
  • Partners: 20 cancer centres in the Czech Republic (you can find more detailed information on the website of the Corect project)
  • Brief overview of results: you can find more detailed information on the website of the Corect project
Corect: Clinical registry of colorectal cancer (CRC) patients who have been treated with cetuximab, bevacizumab and/or panitumumab